Office of Sponsored Programs OSP Weekly
|
|
|
Please forward and share with other faculty who may be interested.
|
|
COVID-19 Funding Opportunities
|
|
The American Diabetes Association (ADA) is requesting applications (
see RFA
) for
research focused on the impact of diabetes on COVID-19 and the impact of COVID-19 on diabetes and its complications
.
Recent clinical results have shown that people with diabetes are at higher risk of death from COVID-19 and that COVID-19 drives an increased risk of hyperglycemia and other complications in those with and without diabetes. This is in addition to the risk due to advanced age and chronic disease. Both the biological mechanisms underlying this risk and how to minimize it remain poorly understood. There is an urgent need for research to understand the impact of diabetes on COVID-19 and vice versa. This is true at a basic and clinical level.
The main text of the application will be a two-page application to provide all necessary study components (Aims, Significance, Preliminary data (if applicable), Research Plan, Expected Actionable Outcomes) with a one-page listing of critical references, PI Biosketch, and budget form. The goal of this RFA is to use a rapid application and review process to identify at least 10 grants of
up to $100,000/each
in this area and of high scientific merit for immediate funding.
The COVID-19 and Diabetes Research Awards
expedited application deadline will be 5pm ET on May 22, 2020
for July 1, 2020 funding.
|
|
|
|
Research Opportunity Announcement
OTA-20-011
Host-targeting Therapies for COVID19
|
|
Given the remarkable variations in severity of SARS-CoV-2 infection among different groups and the striking contributions of lung, cardiac, vascular, and hematologic dysfunction to COVID-19 morbidity and mortality, it is clear that host- and community-related factors are important modulators of COVID-19. It is therefore imperative to test not only antiviral therapies, but also host-targeting treatments that seek to ameliorate tissue injury, enhance reparative responses, and improve health outcomes related to heart, lung, and vasculature by targeting pathobiological processes with organ system or risk group specificity.
This solicitation invites
- Data and Clinical Coordinating Centers that have appropriate expertise in clinical trial design and implementation, as well as existing relationships with a network/consortium of Clinical Centers, to propose inpatient or outpatient trials of host-targeting interventions in patients infected with SARS-CoV-2, designed appropriately for the population and intervention being studied. Although the primary focus of this program is on adaptive design-based testing of interventions in phase II or III drug or therapeutic trials, it is strongly encouraged that proposed studies also include complementary aims such as collecting data, images, and biospecimens; identifying predictive biomarkers; and/or clarifying the pathobiology or the distinctive organ-/individual-specificity of this disease.
- Invites Data and Clinical Coordinating Centers with appropriate expertise and capacity to submit a proposal to serve as the Administrative Coordinating Center for the Network of Networks Platform, outlining the functions, roles, and responsibilities of such a Coordinating Center in ensuring the efficient and effective operations of this COVID-19 Master Clinical Trials Platform and to assist NHLBI in identifying most critical strategic opportunities and to assist in enhancing the likelihood that all funded trials are successful in achieving their scientific goals.
|
|
For best consideration,
initial Stage 1 Letters of Request should be submitted via email by Friday, May 15, 2020, by 5 PM EDT to NHLBI_OTA@mail.nih.gov. Additional letters of request will be considered on a monthly basis (June 15, July 15, August 15). Letters from each of these submission dates may be batched to evaluate multiple proposals together. This mailbox will also be used to answer questions. If invited to submit a Stage 2 full proposal, the applicant will be provided specific instructions for how to submit via eRA ASSIST.
|
ROA: Host-targeting Therapies for COVID19 PDF
|
|
Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions and Administrative Supplements for Coronavirus Disease 2019 (COVID-19) Research within the Mission of NIDCR
|
|
National Institute of Dental and Craniofacial Research (NIDCR) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19). NIDCR will place a high priority on topics that would be of immediate and high impact to protect and
ensure the safety of personnel and patients in dental practices.
These topics include prevention of SARS-COV-2 transmission and improvements in the detection and diagnosis of COVID-19; as well as acquisition of a more robust understanding of SARS-CoV-2 pathogenesis. Further, topics addressing influence and interaction of sex (a biological variable) and gender (a social construct), race and ethnicity, and those addressing questions about risk, prevention, and health outcomes are also of interest.
Application due dates: June 1, 2020, and November 2, 2020, by 5:00 PM local time of applicant organization.
Submit applications for this initiative in response to one of the following funding opportunity announcement (FOA) or the subsequent reissued equivalent through the expiration date of this notice:
- PA-18-591, “Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)”
- PA-18-935: “Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)”
|
|
NIH POCTRN
Fast-Track Program for COVID-19 Test Development and Distribution
Innovative Technologies to Increase U.S. Capacity for COVID-19 Testing
|
|
NIH POCTRN is now accepting proposals for support on a rolling basis until further notice.
The National Institute of Biomedical Imaging and Bioengineering (NIBIB) is urgently soliciting proposals and
can provide up to $500M
across multiple projects to rapidly produce innovative SARS-CoV-2 diagnostic tests that will assist the public’s safe return to normal activities.
Rapid Acceleration of Diagnostics (RADx)
, is a fast-track technology development program that leverages the National Institutes of Health (NIH) Point-of-Care Technology Research Network (
POCTRN
). RADx
will support novel solutions that build the U.S. capacity for SARS-CoV-2 testing up to 100-fold above what is achievable with standard approaches. RADx is structured to deliver innovative testing strategies to the public as soon as late summer 2020 and is an accelerated and comprehensive multi-pronged effort by NIH to make SARS-CoV-2 testing readily available to every American.
NIBIB
is providing substantial support
to accelerate the development, validation, and commercialization of innovative point-of-care and home-based tests, as well as improvements to clinical laboratory tests, that can directly detect SARS-CoV-2, the virus that causes COVID-19. NIBIB will support the full range of product development including commercialization and product distribution.
|
|
|
|
|
|
|
